The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | GEMKyCyDex: KCyd vs Kd in patients with R/R multiple myeloma
Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, gives an overview of the results of GEMKyCyDex, a Phase II study comparing carfilzomib, dexamethasone, and cyclophosphamide (KCyd) with carfilzomib plus dexamethasone (Kd) in patients with relapsed/refractory (R/R) multiple myeloma. Overall, the study did not observe a significant difference between both arms. However, lenalidomide-refractory patients in the KCyd arm had an improved progression-free survival (PFS). The study also reported an increased rate of toxicity in the KCyd arm. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
